Treatments for Ocular Adnexal Lymphoma

Yen, Michael T.; Bilyk, Jurij R.; Wladis, Edward J.; Bradley, Elizabeth; Mawn, Louise A.

doi:10.1016/j.ophtha.2017.05.037

Cited by 48 publications

(23 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is consistent with the current literature that supports the use of EBRT for most cases of primary OEL, especially for low-grade lymphomas such as EMZL, which represented the majority of cases in our series [38][39][40][41][42]. A newly published review by the American Academy of Ophthalmology on treatment of OEL has documented that EBRT has a very good effect on local control, disease-free survival and overall survival in patients with EMZL [43]. EBRT is also the treatment of choice for MCL, which, despite not being a low-grade lymphoma, has been found in some studies to be particularly radiosensitive [23,41,44,45].…”

Section: Discussionsupporting

confidence: 92%

“…Immunotherapy with Rituximab, as sole therapy, was used only in selected cases, namely very old patients with primary low-grade OEL in whom orbital involvement was not causing any quality-of-life issues [ 43 , 51 ]. These patients did not have HBV infection, and the maintenance treatment with Rituximab was done easily with very little morbidity; recurrence was recorded only in one case, after five years.…”

Section: Discussionmentioning

confidence: 99%

“…No association was detected in our study between the T category and recurrence. The AJCC proposed additional factors recommended just for clinical care: the International Prognostic Index (IPI), tumor cell growth fraction (Ki-67, MIB-1) and lactate dehydrogenase level [ 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ]. Nonetheless, these factors were not considered in this series as complete data were available only for a small percentage of studied patients.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Orbital and Eyelid B-Cell Lymphoma: A Multicenter Retrospective Study

Savino

Midena

Blasi

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: The aim of this study was to analyze patients diagnosed, staged and treated for orbital and eyelid B-cell lymphoma (OEL). Methods: One hundred and forty-one cases of OEL were included in this study. Primary endpoints were to analyze the histopathologic findings, the main risk factors and the type of treatment and to correlate them with recurrence of OEL. The secondary endpoint was to determine the progression-free survival (PFS) time. Results: Extranodal marginal zone B-cell lymphoma was the most frequent subtype (66%), followed by small lymphocytic lymphoma (12.7%), diffuse large B-cell lymphoma (DLBCL) (9.2%), follicular lymphoma (6.6%), mantle cell lymphoma (4.3%) and Burkitt lymphoma (1.2%). The probability of relapse was influenced by the histopathologic subtype DLBCL (OR = 7.7, 95% CI 1.8–32.3) and treatment with chemotherapy (OR = 14.9, 95% CI 2.6–83.7). Multivariate analysis showed that the histopathologic subtype DLBCL and chemotherapy treatment retained statistical significance for a poorer PFS, with hazard ratios of 8.581 (p = 0.0112) and 9.239 (p = 0.0094), respectively. Conclusions: Five lymphoma subtypes were found in patients with OEL. The histopathologic subtype and the type of treatment were found to be the main factors influencing treatment outcome.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Orbital and Eyelid B-Cell Lymphoma: A Multicenter Retrospective Study

Savino

Midena

Blasi

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…In the case of MALT lymphoma alone, the overall local control rate was 96% at 5 years and 86% at 10 years (range, 23.1-45 Gy; median D1.8, 31.8 Gy) [63]. As noted in many studies, radiation therapy shows a good local control rate, but it can cause some adverse effects, including cutaneous reactions, cataracts, dry eyes, macular degeneration, retinopathy, and corneal ulceration, particularly at doses of 30 Gy or higher [64][65][66][67].…”

Section: Radiation Therapymentioning

confidence: 87%

Ocular adnexal mucosa-associated lymphoid tissue lymphoma: a narrative review

Chung

Son

2022

J Yeungnam Med Sci

View full text Add to dashboard Cite

Lymphoma is a type of blood malignancy that begins in lymphocytes which include B-lymphocytes, T-lymphocytes, and natural killer (NK) cells. There are two main categories of lymphoma: those presenting with a specific type of cellular abnormality dubbed a Reed-Sternberg cell, called classic Hodgkin lymphomas (HLs), and the others called non-Hodgkin lymphomas (NHLs) [1]. HL accounts for approximately 10% of all lymphomas, while the remaining 90% are NHL [2]. NHL is also divided into B-cell and T-cell lymphomas. B-cell lymphoma accounts for more than 85% of all lymphoid neoplasms [1]. Although orbital lymphoma is rare, accounting for only 1% of all NHL cases, it is the most common primary orbital cancer in adults, accounting for 55% of all malignancies in the orbit [3][4][5]. The majority of NHL of the orbit and

show abstract

“…This disease comprises 55% of orbital tumors and 8% of extranodal lymphomas [12]; the most frequent subtype is extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). MALT lymphoma, which originates in B-cells, represents approximately 75% of primary ocular adnexal lymphomas [345]. Common sites of primary ocular adnexal MALT lymphoma (POML) are the orbit, conjunctiva, and lacrimal apparatus.…”

Section: Introductionmentioning

confidence: 99%

Clinical presentation and treatment outcomes of primary ocular adnexal MALT lymphoma in Thailand

et al. 2018

View full text Add to dashboard Cite

BackgroundPrimary ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (POML) is the most common subtype of lymphoma involving the eyes in Thailand. We sought to assess the characteristics and treatment outcomes of patients with POML in Thailand.MethodsWe retrospectively reviewed patient data and included patients diagnosed with POML between January 2004 and December 2016 at Chiang Mai University Hospital and King Chulalongkorn Memorial Hospital, Thailand. We collected and analyzed patients' clinical characteristics and treatment outcomes.ResultsAmong 146 patients with lymphoma involving the eyes, 121 (82%) were diagnosed with POML. Sixty-four (52.9%) were women with median age 58 (range, 22–86) years. The most common presenting symptom was orbital mass (71.1%). Common sites of origin were the orbit (46.3%) and lacrimal gland (34.7%). At presentation, 22.3% of patients had bilateral eye involvement. About half of patients had stage I disease (N=59, 56.2%) and 20% had stage IV. Most patients (73.3%) had a low-risk International Prognostic Index. Radiotherapy was the main treatment for patients with limited-stage disease (66.7% in stage I and 56.5% in stage II). The overall response rate was 100% with complete response rates 80%, 77.3%, and 64.7% for stages I, II, and IV, respectively. Five-year progression-free survival (PFS) and overall survival were 66.1% and 94.0%, respectively. For patients with limited-stage disease, radiotherapy significantly improved PFS compared with treatment not involving radiotherapy (5-year PFS 89.9% vs. 37.3%, P=0.01).ConclusionWe revealed that POML has good response to treatment, especially radiotherapy, with excellent long-term outcome.

show abstract

Treatments for Ocular Adnexal Lymphoma

Abstract: For MALT lymphomas, local control, disease-free survival, and overall survival are good with radiation treatment. The results of treatment of non-MALT lymphomas using radiotherapy also were good, but they were not as favorable as the treatment results of MALT lymphomas.

Cited by 48 publications

References 46 publications

Orbital and Eyelid B-Cell Lymphoma: A Multicenter Retrospective Study

Orbital and Eyelid B-Cell Lymphoma: A Multicenter Retrospective Study

Ocular adnexal mucosa-associated lymphoid tissue lymphoma: a narrative review

Clinical presentation and treatment outcomes of primary ocular adnexal MALT lymphoma in Thailand

Contact Info

Product

Resources

About